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Abstract
Necrotizing enterocolitis (NEC) is the leading cause of gastrointestinal morbidity and mortality in preterm infants. NEC is
characterized by an exaggerated inflammatory response to bacterial flora leading to bowel necrosis. Bacterial
lipopolysaccharide (LPS) mediates inflammation through TLR4 activation and is a key molecule in the pathogenesis of
NEC. However, LPS also induces cyclooxygenase-2 (COX-2), which promotes intestinal barrier restitution through stimulation
of intestinal cell survival, proliferation, and migration. Epidermal growth factor receptor (EGFR) activation prevents
experimental NEC and may play a critical role in LPS-stimulated COX-2 production. We hypothesized that EGFR is required
for LPS induction of COX-2 expression. Our data show that inhibiting EGFR kinase activity blocks LPS-induced COX-2
expression in small intestinal epithelial cells. LPS induction of COX-2 requires Src-family kinase signaling while LPS
transactivation of EGFR requires matrix metalloprotease (MMP) activity. EGFR tyrosine kinase inhibitors block LPS stimulation
of mitogen-activated protein kinase ERK, suggesting an important role of the MAPK/ERK pathway in EGFR-mediated COX-2
expression. LPS stimulates proliferation of IEC-6 cells, but this stimulation is inhibited with either the EGFR kinase inhibitor
AG1478, or the selective COX-2 inhibitor Celecoxib. Taken together, these data show that EGFR plays an important role in
LPS-induction of COX-2 expression in enterocytes, which may be one mechanism for EGF in inhibition of NEC.
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Introduction
Necrotizing enterocolitis (NEC) is the leading gastrointestinal
medical and surgical emergency in premature infants and is the
cause of significant mortality and morbidity in this vulnerable
population [1–3]. NEC is characterized by invasion of the intestine
by bacteria followed by an acute, hyper-reactive inflammatory
cascade, which leads to loss of epithelial integrity and subsequent
bowel necrosis. This process results in up to a 30% mortality rate
with severe gastrointestinal and developmental morbidity in
survivors [4].
Lipopolysaccharide (LPS) induced activation of the innate
immunity pattern recognition molecule Toll-like receptor 4
(TLR4) is associated with increased incidence of NEC in both
mice and humans [5,6]. LPS is a large lipid and polysaccharide
structure that is the major component of the outer cell wall of
Gram-negative bacteria and acts as an endotoxin. In addition to
activating TLR4, LPS has been shown to induce the production of
cyclooxygenase-2 (COX-2) in small intestinal epithelial cells [7].
COX-2 is a rate-limiting enzyme in the synthesis of prostanoids
from their precursor, arachidonic acid. Elevated COX-2 levels
have been demonstrated in both human NEC and animal models
of the disease [7,8]. However, the exact role of COX-2 in NEC
pathogenesis remains unclear to date. COX inhibitors such as
nonsteroidal anti-inflammatory drugs and glucocorticoids have
been linked to neonatal bowel injury [9], and suppression of
COX-2 with selective COX-2 inhibitors causes exacerbation of
experimental NEC and results in bowel perforation [7,10]. These
findings imply a potential protective role of COX-2 in the
intestinal epithelial cells and point to an important role of COX-2
in the reparative response to intestinal injury [11,12].
Epidermal growth factor (EGF) is critical for the maturation of
the fetal and neonatal gastrointestinal tract [13]. EGF is expressed
in high concentrations in amniotic fluid, saliva, and breast milk
[13], and has been shown to decrease the incidence of NEC in
animal models of the disease [14]. EGF signals primarily through
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the EGF receptor (EGFR), which is a transmembrane glycoprotein
with intrinsic tyrosine kinase activity. EGFR is expressed on
enterocytes where it induces repair mechanisms following gastro-
intestinal mucosal injury, promotes cell survival, reduces intestinal
inflammation and protects against experimental NEC [14–18]. In
addition to direct activation by EGF, EGFR can be transactivated
indirectly by various extracellular stimuli, including LPS [19].
These transactivation events are important in intestinal epithelial
barrier maintenance and can protect the epithelium from
apoptosis [20]. Since both LPS and COX-2 are associated with
NEC, we sought to test the hypothesis that LPS-mediated COX-2
expression requires EGFR transactivation. Improved insight in the
mechanisms regulating enterocyte EGFR and COX-2 signaling is
critical for a better understanding of NEC pathogenesis and for
developing new targets for therapeutic interventions.
Materials and Methods
Cell culture
IEC-6 cells (ATCC, Manassas, VA) were grown as a monolayer
in DMEM media supplemented with 5% FBS (Hyclone), 0.1%
Insulin-Transferrin-Selenium (ITS) and 1% Penicillin/Streptomy-
cin (BD Biosciences, San Jose, CA), in a humidified atmosphere
containing 5% CO2. Prior to experiments, cells were cultured for
24 hours and then serum starved in DMEM media without FBS
for 16 hours. Unless otherwise noted, the cells were then treated
with 2 mg/mL LPS from Escherichia coliO127:B8 (Sigma, St. Louis,
MO) or 10 ng/mL murine EGF (Peprotech, Rocky Hill, NJ) for
the indicated durations. In pharmacologic studies, IEC-6 cells
were pre-treated with inhibitors for 1 hour before further
stimulation.
Antibodies and inhibitors
Western blot antibodies used for these experiments included:
beta-Actin (Sigma, St. Louis, MO), COX-1 and COX-2 (Cayman
Chemical, Ann Arbor, MI), anti-rabbit and anti-mouse horserad-
ish peroxidase-conjugated secondary antibodies, phospho-Y845-
EGFR, phospho-ERK1/2, ERK1/2, and phospho-p38 (Cell
Signaling Technology, Beverly, MA). Anti-EGFR antibodies were
purchased from Millipore (Bedford, MA) and HRP-conjugated
anti-phospho-tyrosine antibody was purchased from BD Bios-
ciences (Franklin Lakes, NJ). Specific inhibitors were from the
following sources: EGFR kinase inhibitor AG1478, MMP in-
hibitor GM6001, p38 MAPK inhibitor SB202190 were purchased
from EMD Chemicals (Gibbstown, NJ); the ERK1/2 inhibitor
U0126 was purchased from Cell Signaling Technology (Boston,
MA); and the selective COX-2 inhibitor Celecoxib was purchased
from Sigma (St. Louis, MO).
Cell lysates and Western blotting
Cell monolayers were washed twice with ice cold PBS and
scraped on ice into cold lysis buffer (1% Triton X-100, 10%
150 mM NaCl, 50 mM Tris, pH 7.4). Cellular lysates were
cleared and boiled in Laemmli sample buffer [30]. Protein
expression and phosphorylation was determined by Western blot
analysis.
Immunoprecipitation
Cellular lysates were pre-cleared by incubating with protein AG
agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) for
30 min followed by centrifugation. Supernatants were incubated
with 2 mg anti-EGFR antibody for 1 hour at 4uC, and then for
1 hour at 4uC with protein AG agarose beads. Immunocomplexes
were collected by centrifugation, washed three times in lysis buffer,
and boiled in Laemmli sample buffer for SDS-PAGE Western blot
analysis.
Figure 1. LPS induces COX-2 in IEC-6 cells. A) IEC-6 cells were treated with the indicated concentrations of LPS for 24 hours. B) IEC-6 cells were
treated with 2 mg/mL LPS for the indicated time. C) IEC-6 cells were treated with LPS (2 mg/mL) for the indicated times. D) Cells were treated with LPS
(2 mg/mL), EGF (10 ng/mL), or co-treated with LPS and EGF for 24 hours. Protein expression was determined by Western blot analysis and
densitometry. Treatment with LPS did not induce COX-1 expression in IEC-6 cells. In contrast, treatments with LPS, EGF, or both significantly increased
COX-2 expression compared to control (p,0.001, = 0.05, and ,0.001 respectively). Cells treated with LPS and EGF had significantly greater COX-2
expression than by either EGF (p = 0.002) or LPS (p = 0.006) alone. Single asterisks indicate significant differences from control. Double asterisks
indicate significant differences between two bracketed conditions.
doi:10.1371/journal.pone.0038373.g001
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Cell proliferation assays
1.756104 IEC-6 cells/well were seeded in 24-well plate wells
and grown for 24 hours in DMEM media (supplemented with
FBS and ITS) followed by serum starvation for 16 hours. The cell
monolayers were pretreated with inhibitors for 1 hour followed by
treatment with or without LPS for 48 hours. Cells were counted
using a Nucleocounter (New Brunswick, Edison, NJ) using
manufacturers protocols.
Replicates and statistical analysis
All data are representative of at least three independent
experiments. Statistical significance of differences between means
from two groups was assessed with a Student’s t-test analysis.
When comparisons were made amongst three or more groups,
analysis of variance was applied first as a global test for differences.
Pre-determined pair-wise comparisons were then made using
Student’s t-test only when an overall effect was detected through
analysis of variance. Minimum level of significance was set at 0.05.
Results
LPS and EGF induce COX-2 protein expression in IEC-6
cells
To determine the optimal conditions for LPS stimulation of
COX-2, IEC-6 cells were treated with varying concentrations of
LPS (Fig. 1A) and for various time periods (Fig. 1B) as shown. We
chose the 24-hour time-point for our studies, because the level of
COX-2 protein induction was the strongest and most reproducible
at that time by Western blot. Twenty-four hour treatments with
LPS induced COX-2 expression at all concentrations, but the
induction was most consistent at 2 mg/mL, which was the LPS
dose chosen for the remainder of the experiments unless otherwise
noted. At 2 mg/mL LPS induced COX-2 beginning at 1 hour of
treatment and persisting for at least 24 hours (Fig. 1B). To
determine if LPS specifically induced COX-2, we examined LPS-
treated IEC-6 cells for COX-1 induction. LPS caused no
induction of COX-1 at any time point (Fig. 1C). Since both
LPS and EGF have been shown to stimulate COX-2, we next
Figure 2. Transactivation of EGFR by LPS induces COX-2 expression in IEC-6 cells in an MMP- and p38-dependent fashion. A) IEC-6
cells were treated with LPS (2 mg/mL) for the indicated time or with EGF (10 ng/mL) for 5 minutes. EGFR immunoprecipitates were assayed for P-
EGFR by Western blot analysis. B) Western blot analysis of cells treated with LPS (2 mg/mL) or EGF (10 ng/mL) for 24 hours in the presence or absence
of the EGFR kinase inhibitor AG1478 (1 mM). C) IEC-6 cells were stimulated with LPS (2 mg/mL) for 24 hours in the presence or absence of the Src
family kinase inhibitor CGP77675 (2 mM) or the MMP inhibitor GM6001 (50 mM). D) IEC-6 cells were stimulated with LPS (2 mg/mL) for 15 minutes in
the presence or absence of CGP77675 (2 mM), GM6001 (50 mM), or p38 MAPK inhibitor SB202190 (10 mM). Single asterisks indicate significant
differences from control. Double asterisks indicate significant differences between two bracketed conditions.
doi:10.1371/journal.pone.0038373.g002
Role of EGFR in LPS-Induced COX-2 Expression
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e38373
Figure 3. ERK and Src, but not p38, are required for EGFR-mediated induction of COX-2. A) IEC-6 cells were treated with LPS (2 mg/mL) for
15 minutes or with EGF (10 ng/mL) for 5 minutes in the presence or absence of the EGFR kinase inhibitor AG1478 (1 mM). Western blot analysis of P-
p38 MAPK showed no significant difference in p38 activation in the presence of EGFR inhibition. B) IEC-6 cells stimulated with LPS (2 mg/mL) for
15 minutes or with EGF (10 ng/mL) for 5 minutes in the presence or absence of AG1478 (1 mM). C) IEC-6 cells were treated with LPS (2 mg/mL) for
24 hours or with EGF (10 ng/mL) for 5 minutes in the presence or absence of the ERK1/2 inhibitor U0126 (10 mM) or the p38 inhibitor SB202190
(10 mM) as shown, and COX-2 expression was determined using Western blot analysis. D) IEC-6 cells were treated with EGF (10 ng/mL) for 5 minutes
in the presence or absence of the Src family kinase inhibitor CGP77675 (2 mM) and analyzed for P-ERK activation using Western blot analysis. Src
inhibition had no effect on EGF-induced P-ERK (p = 0.7). IEC-6 cells were also treated with EGF (10 ng/mL) for 5 minutes in the presence or absence of
the ERK kinase inhibitor U1026 (10 mM) and analyzed for P-Src activation using Western blot analysis. ERK inhibition had no effect on EGF-induced P-
Src activation (p = 0.17). Single asterisks indicate significant differences from control. Double asterisks indicate significant differences between two
bracketed conditions.
doi:10.1371/journal.pone.0038373.g003
Figure 4. Stimulation of IEC-6 cell proliferation by LPS requires COX-2 activity. IEC-6 cells were treated with LPS (2 mg/mL) for 48 hours in
the presence or absence of A) Celecoxib (10 mM) or B) AG1478 (1 mM). Cell numbers were determined by a Nucleocassette counter. Celecoxib and
AG1478 treatment significantly blocked LPS-induced proliferation (p = 0.03 and 0.001 respectively).
doi:10.1371/journal.pone.0038373.g004
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attempted to determine if the effects of LPS and EGF were
additive. IEC-6 cells were treated with LPS, EGF, or both and
compared to controls (Fig. 1D). Treatment of IEC-6 cells with
either LPS or EGF significantly increased COX-2 expression over
controls (p,0.001 for LPS and p= 0.05 for EGF). However,
combined LPS and EGF treatments significantly increased COX-
2 expression over controls (p,0.001) and over both LPS
(p = 0.006) and EGF (p= 0.002) treatments alone. This suggests
that LPS and EGF can induce COX-2 through separate pathways,
although we cannot exclude a converging pathway downstream.
Transactivation of EGFR by LPS induces COX-2 expression
in IEC-6 cells
LPS and EGF can both stimulate COX-2 expression directly,
however, LPS has also been shown to transactivate EGFR in
intestinal epithelial cells [19]. To understand the potential role of
EGFR transactivation in LPS stimulation of COX-2 we first
examined the ability of LPS to directly stimulate EGFR
phosphorylation. In IEC-6 cells treated with LPS for varying
times, increased phosphorylation of EGFR was observed after 5–
60 minutes of treatment (Fig. 2A). Since LPS induces both COX-2
expression and EGFR phosphorylation, and activation of EGFR
can induce COX-2, we wanted to determine if EGFR was
required for LPS-induced activation of COX-2. To examine the
requirement of EGFR, IEC-6 cells were pretreated with AG1478,
a small molecule inhibitor of EGFR kinase activity, prior to
treatment with LPS or EGF. Pretreatment of IEC-6 cells with
AG1478 significantly reduced both LPS- and EGF-induced COX-
2 expression, indicating that EGFR is important for both LPS and
EGF induction pathways of COX-2 (p= 0.02 and 0.03, re-
spectively) (Fig. 2B).
Transactivation of EGFR by LPS requires MMP and p38
activity
Our data show that transactivation of EGFR by LPS plays a role
in COX-2 induction. To further understand the mechanism of this
pathway, we next examined the role of two known signaling
pathways involved in EGFR transactivation, Src family kinases
and matrix metalloproteases, in activation of COX-2 by LPS and
EGF. IEC-6 cells were pretreated with CGP77675 (a specific Src
family kinase inhibitor) or GM6001 (a general MMP inhibitor),
prior to stimulation with either LPS or EGF. COX-2 protein
expression was measured by Western blot analysis (Fig. 2C). The
Src family inhibitor CGP77675 significantly decreased basal, LPS-
induced, and EGF-induced expression of COX-2 (p = 0.002, 0.04,
and 0.04 respectively). By contrast, the MMP inhibitor GM6001
had no effect on either basal or induced COX-2 expression. These
data support the hypothesis that LPS induces COX-2 through
a Src-dependent mechanism. To determine if Src family members,
or MMPs play a role in the activation of EGFR by LPS, IEC-6
cells were pretreated with CGP77675 or GM6001 prior to
stimulation with LPS. GM6001 blocked baseline and LPS-
stimulated activation of EGFR (p= 0.008 and 0.002 respectively)
(Fig. 2D), suggesting that MMPs are required for activation of
EGFR by LPS. While the Src family inhibitor CGP77675 blocked
EGF-stimulated activation of COX-2, it had no effect on LPS-
induced phosphorylation of EGFR, suggesting that Src is involved
downstream of EGFR transactivation. We additionally examined
the role of the MAPK p38 in LPS activation of EGFR, which
previously has been reported to play a role in LPS induced
expression of COX-2 [7,21]. IEC-6 cells were pretreated with the
p38 inhibitor SB202190 prior to treatment with LPS. Inhibition of
p38 significantly blocked transactivation of EGFR by LPS
Figure 5. Proposed mechanism of LPS-induced COX-2 stimulation via EGFR transactivation. LPS can induce COX-2 production either
directly through TLR-4 signaling or via EGFR transactivation. EGFR transactivation requires p38 and MMP activity. Following EGFR transactivation,
COX-2 production can be stimulated either through ERK- or Src-mediated pathways. Although our data suggest that LPS and EGF can induce COX-2
expression through separate pathways, we cannot exclude that the pathway merges downstream prior to transcription.
doi:10.1371/journal.pone.0038373.g005
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(p = 0.009) (Fig. 2D). Taken together, these data suggest that LPS-
induced transactivation of EGFR requires the activity of MMPs
and p38, whereas LPS- and EGF-induced expression of COX-2
require the activity of Src family kinases.
LPS couples to EGFR downstream activation of MAPK ERK
Grishin et al previously reported that LPS induces COX-2 via
a noncanonical p38 MAPK pathway in IEC-6 cells [7,21]. Our
data show that p38 is necessary for activation of EGFR by LPS
(Fig. 2D). Therefore, we tested whether transactivation of EGFR
by LPS is coupled to p38 MAPK activation. IEC-6 cells were
pretreated with AG1478 followed by stimulation with LPS or
EGF. While p38 was required for LPS activation of EGFR,
blocking EGFR kinase activity did not inhibit p38 activation by
either LPS or EGF (Fig. 3A), suggesting that p38 is involved in
a pathway of EGFR transactivation that does not depend on
EGFR kinase activity. To gain insight into the mechanism of
COX-2 induction via EGFR we analyzed the ERK/MAPK,
which is another downstream signaling target of EGFR. IEC-6
cells were pretreated with AG1478 followed by treatment with
LPS or EGF, and ERK activation was examined with Western
blot analysis (Fig. 3B). Both LPS and EGF were stimulated ERK
activation. Blocking the EGFR kinase activity with AG1478
significantly reduced both LPS- and EGF-induction of ERK
(p= 0.04 and 0.004 respectively) implicating ERK as a signaling
target of activated EGFR. To determine whether ERK activity
plays a role in LPS-induced expression of COX-2, we pretreated
cells with U0126, an inhibitor of the ERK signaling pathway prior
to treatment with either LPS or EGF (Fig. 3C). Blocking ERK
activation significantly inhibited both LPS- and EGF- induced
expression of COX-2 (p= 0.03 and 0.0005 respectively), indicating
an important role of the ERK pathway in COX-2-induction
downstream of LPS-transactivated EGFR. We repeated this
experiment using the p38 inhibitor SB202190 to determine if
p38 inhibition would have similar effects. Blocking p38 activity
significantly inhibited baseline and EGF-induced but not LPS-
stimulated expression of COX-2 (p= 0.01).
Since our data indicated that both ERK and Src are required
for EGFR activation of COX-2, we next sought to determine if
these two kinases act in the same pathway or in distinct pathways.
IEC-6 cells were pre-treated with either the Src inhibitor
CGP77675 or the ERK inhibitor U0126 prior to treatment with
EGF. Cells were examined for phosphorylation of ERK and Src
by Western blot analysis (Fig. 3D). Neither inhibitor was able to
quench the downstream activation of the intended target implying
that Src and ERK belong to different downstream pathways of
EGFR-induced COX-2 expression.
COX-2 and EGFR inhibition both block LPS-stimulated
cell proliferation
LPS-induced COX-2 expression has been proposed to play
a role in enterocyte proliferation [22,23]. Therefore, we tested the
hypothesis that disruption of LPS induction of COX-2 both
directly and through disruption of EGFR transactivation would
reduce IEC-6 cell growth. Treatment of IEC-6 cells with LPS
stimulated proliferation, which is consistent with the mitogenic
effects of EGFR and ERK (Fig. 4A and 4B). Both the selective
COX-2 inhibitor Celecoxib (Fig. 4A) and the selective EGFR
inhibitor AG1478 (Fig. 4B) were able to significantly decrease
LPS-induced proliferation (p= 0.03 and 0.001 respectively). These
data further demonstrate an overlap in the biological activities of
EGFR and COX-2, and suggest that COX-2 and EGFR play
critical roles in the mitogenic response to LPS.
Discussion
This study delineates an important pathway of LPS-induced
COX-2 upregulation through EGFR transactivation, suggesting
a novel role of EGFR in enterocyte homeostasis and, potentially,
in the protection against NEC. Although the pathogenesis of NEC
continues to be explored, the unifying hypothesis includes mucosal
injury of the small intestine, followed by bacterial translocation
and an exaggerated inflammatory response to endotoxin (LPS)
[24]. LPS binds Toll-like receptor 4 (TLR4), leading to activation
of nuclear factor (NF)-kB and subsequent proinflammatory
cytokine release by enterocytes and other cells [25]. Despite this
proinflammatory mechanism, the role of LPS in inflammatory
disorders of the intestine is not entirely clear. Whereas LPS has
been shown to reduce enterocyte migration and proliferation via
TLR4, which may impair intestinal healing [26,27], LPS-induced
COX-2 expression stimulates proliferation of colonocytes and
repair of colonic epithelium [22]. Regarding the pathophysiology
of NEC, several reports have demonstrated the role of TLR4 as
causative for the disease [6,28], and yet Grishin and colleagues
reported LPS stimulation of COX-2 was protective in experimen-
tal NEC [7]. Our data help to explain this dichotomy by showing
that LPS can induce COX-2 expression in enterocytes through
EGFR transactivation. Although our data suggests that LPS and
EGF can induce COX-2 through separate pathways, we cannot
exclude a converging pathway downstream.
One goal of this study was to identify signaling pathways that
mediate COX-2 induction after LPS transactivation of EGFR. By
using specific inhibitors of EGFR kinase activity we established
that induction of COX-2 by LPS involves EGFR transactivation.
Our data also demonstrate that transactivation of EGFR by LPS is
dependent on p38 and MMP activity. Once EGFR is transacti-
vated, further induction of COX-2 depends on activation of ERK
and Src, two downstream targets of EGFR. Whereas both ERK
and Src are required for induction of COX-2 by LPS via
transactivation of EGFR, they appear to act in distinct parallel
pathways (Fig. 5).
We speculate that MMPs are involved in transactivation of
EGFR by LPS, but none of these phosphotyrosines on EGFR
couple to COX-2 induction. In this case Src may actually be
involved in transactivation of EGFR phosphotyrosines that do
couple to COX-2 activation, but these phosphotyrosines are not
visible to the phosphotyrosine antibody that we used in this study.
Grishin and colleagues previously reported an essential role of
the p38 MAPK in COX-2 upregulation in enterocytes [7,21]. Our
data show that p38 is required for LPS induced transactivation of
EGFR, but not for subsequent EGFR-mediated COX-2 in-
duction. Thus, inflammatory upregulation of COX-2 in the
intestine is more complex than previously thought and may
involve p38-dependent and p38-independent pathways.
Our central finding is the critical involvement of EGFR in LPS-
induced COX-2 expression in enterocytes. EGFR is abundantly
expressed in premature intestinal epithelial cells [29] and EGFR
and its ligands have long been recognized as protective factors in
NEC [18,30–32]. The significance of MAPK-independent EGFR
signaling in LPS-induced wound repair has been previously
described in airway epithelial cells [33]. Interestingly, the effects of
LPS on wound healing were dose-dependent [33], which is yet
another illustration of the delicate balance between injury and
repair that characterizes the complex molecular pathways in
epithelium-microbial interactions. The effects of LPS and EGF on
EGFR signaling may also be time-dependent. While prolonged
receptor stimulation with LPS did not increase COX-2 expression
compared to 24 hour pretreatment alone, sustained stimulation
Role of EGFR in LPS-Induced COX-2 Expression
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for 6 hours with EGF enhanced the COX-2 signal by Western
blot (data not shown).
Inhibition of LPS-stimulated enterocyte proliferation by the
selective COX-2 inhibitor Celecoxib, and by the selective EGFR
kinase inhibitor AG1478 implies a possible role of EGFR-
mediated induction of COX-2 in epithelial restitution. Based on
our data, we propose a role of EGFR transactivation by LPS in the
inflammatory upregulation of COX-2 in the intestine.
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